Vanda Pharmaceuticals (VNDA) Cash & Current Investments (2010 - 2026)

Vanda Pharmaceuticals has reported Cash & Current Investments for 17 years, with the latest figure at $202.3 million in Q1 2026.

• Quarterly Cash & Current Investments fell 40.66% year-over-year to $202.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $202.3 million (down 40.66% YoY) and the FY2025 annual result came in at $263.8 million, down 29.57% from the prior year.
• Cash & Current Investments fell to $202.3 million in Q1 2026 per VNDA's latest filing, from $263.8 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $501.5 million in Q1 2023 and troughed at $202.3 million in Q1 2026.
• A 5-year average of $389.7 million and a median of $388.3 million in 2023 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2026: Cash & Current Investments advanced 15.24% in 2023, then tumbled 40.66% in 2026.
• Over 5 years, Cash & Current Investments stood at $466.9 million in 2022, then decreased by 16.83% to $388.3 million in 2023, then slipped by 3.51% to $374.6 million in 2024, then dropped by 29.57% to $263.8 million in 2025, then dropped by 23.32% to $202.3 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $202.3 million, $263.8 million, and $293.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.